Clinical Trial Update: A Pilot-Study With Low-dose hrIL-2 for the Treatment of Systemic Lupus Erythematosus [Phase 2]

View source ↗

Summary

A Phase 2 pilot study is evaluating low-dose hrIL-2 for the treatment of Systemic Lupus Erythematosus, with the study status currently unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• hrIL-2 (human recombinant interleukin-2)

Snippet

Sponsor: Peking University People's Hospital | Conditions: Systemic Lupus Erythematosus | Phase 2 | Status: UNKNOWN